



Stakeholder workshop on small particles and nanoparticles in food, 30 March – 1 April 2022

## Overview of the EFSA Guidance on Nano – Risk Assessment

Irene Cattaneo  
EFSA Methodology and Scientific Support Unit

Trusted science for safe food

# Guidance on Nano – Risk Assessment

EFSA Scientific Committee, 2021. Guidance on risk assessment of nanomaterials to be applied in the food and feed chain: human and animal health. EFSA Journal 2021;19(8):6768, 111 pp. <https://doi.org/10.2903/j.efsa.2021.6768>



## GUIDANCE

ENDORSED: 29 May 2018  
doi: 10.2903/j.efsa.2018.5327

### Guidance on risk assessment of the application of nanoscience and nanotechnologies in the food and feed chain: Part 1, human and animal health

EFSA Scientific Committee,  
Anthony Hardy, Diane Benford, Thorhallur Halldorsson, Michael John Jeger, Helle Katrine Knutsen, Simon More, Hanspeter Naegeli, Hubert Noteborn, Colin Ockleford, Antonia Ricci, Guido Rychen, Josef R. Schlatter, Vittorio Silano, Roland Solecki, Dominique Turck, Maged Younes, Qasim Chaudhry, Francesco Cubadda, David Gott, Agnes Oomen, Stefan Weigel, Melpo Karamitrou, Reinhilde Schoonjans and Alicja Mortensen



## GUIDANCE

ADOPTED: 30 June 2021  
doi: 10.2903/j.efsa.2021.6768

### Guidance on risk assessment of nanomaterials to be applied in the food and feed chain: human and animal health

EFSA Scientific Committee,  
Simon More, Vasileios Bampidis, Diane Benford, Claude Bragard, Thorhallur Halldorsson, Antonio Hernández-Jerez, Susanne Hougaard Bennekou, Kostas Koutsoumanis, Claude Lambré, Kyriaki Machera, Hanspeter Naegeli, Søren Nielsen, Josef Schlatter, Dieter Schrenk, Vittorio Silano (deceased), Dominique Turck, Maged Younes, Jacqueline Castenmiller, Qasim Chaudhry, Francesco Cubadda, Roland Franz, David Gott, Jan Mast, Alicja Mortensen, Agnes G. Oomen, Stefan Weigel, Eric Barthelemy, Ana Rincon, José Tarazona and Reinhilde Schoonjans

2018



2021

## Guidance update:

- **Original focus** maintained
- **Scientific knowledge updates**
- Improved “**usability**” gained by the experience with actual cases from the Pilot phase
- Legal clarifications from DG SANCO on the applicability of the definitions under the **Novel Food** (Regulation (EU) 2015/2283) and **REACH Regulations** ((EU) 2018/1881, (EU) 2020/878)
- **JRC, EU MSs, ECHA, DG SANTE** cooperation and input
- EFSA complementary **Guidance on Particle - TR**

# Scope and when to apply this Guidance

A full assessment is required if the applicant or the risk assessor concludes that the material:


- a) meets the criteria of the definition of **engineered nanomaterials** of the Novel Food Regulation (EU) No 2015/2283;
- b) is **a substance to be used to manufacture FCMs**, which is in **nanof orm** in accordance with Article 9(2) of Commission Regulation (EU) 10/2011, or deliberately engineered to particle size which **exhibit functional physical and chemical properties** that significantly differ from those at a larger scale in accordance to Article 5(2)(c)(ii) of Commission Regulation (EC) No 450/2009;
- c) is **an active substance in PPPs**, consisting of or containing **nanof orms** according to the provisions of Commission Regulations (EU) 2018/1881, and (EU) 2020/878, amending the Annexes I, II, III, VI, VII, VIII, IX, X, XI, and XII of the REACH Regulation to introduce nanospecific clarifications, or is a **PPP with co-formulants in nanof orm**;
- d) does **not meet the above-mentioned legal definitions (a, b, c) but consists of or contains a fraction of small particles** requiring assessment in the nanoscale, identified according to the Guidance on Particle-TR, setting out information requirements for applications in the regulated food and feed product areas, and establishing criteria for assessing the presence of a fraction of small particles;
- e) is a **nanof ormed material** or a material, including **materials formulated in the form of nanocarriers** (see Appendix D.5), which could retain properties that are characteristic of the nanoscale, for example related to the large specific surface area of the materials or different toxicokinetic behaviour (i.e. significant changes in absorption, distribution and/or metabolism) as compared to its non-nanomaterial.



## Audience:

This Guidance should be considered by the **applicants** when preparing the application/dossier, and then by the EFSA Panels and Units when assessing the information submitted.

# How to use this Guidance in relation to sectoral EFSA guidances



This Guidance is **complementary** to the EFSA Guidance documents on conventional materials

## Nine Chapters

1. Introduction: Background, Terms of Reference, Scope, How to use the guidance
  2. Data and methodologies
  3. Risk assessment of nanomaterials: general outline
  4. Materials to be assessed under this Guidance
  5. Physicochemical characterisation of nanomaterial
  6. Oral exposure assessment of nanomaterial
  7. Hazard identification and hazard characterisation of nanomaterial
  8. Risk characterisation of nanomaterial
  9. Uncertainty analysis of nanomaterial risk assessment
- References, Abbreviations, Glossary

## Four Appendices


- Appendix A. Demonstration fact sheet for component 2
- Appendix B. Characterisation techniques
- Appendix C. Uncertainty analysis of high dissolution/degradation rate
- Appendix D. Additional information on specific regulated products
  - D.1 Feed additives / D.2 Pesticides / D.3 Substances used in Food Contact Materials (FCM) / D.4 Nanofibres / D.5 Nanocarriers / D.6 Fertilisers



# Guidance structure (2)


## Schematic outline for the implementation linking the Chapters

### STEP 1: IDENTIFICATION OF MATERIALS REQUIRING NANOSPECIFIC ASSESSMENT AND THEIR PHYSICOCHEMICAL CHARACTERISATION (Chapters 4 and 5)




Chapter 4. Materials to be assessed under this Guidance

Chapter 5. Physicochemical characterisation of nanomaterial





Chapter 6. Oral exposure assessment of nanomaterial

Chapter 7. Hazard identification and hazard characterisation of nanomaterial




Chapter 8. Risk characterisation of nanomaterial

Chapter 9. Uncertainty analysis of nanomaterial risk assessment




# Chapter 4: Materials to be assessed under this Guidance



**Figure 3:** Step 1 includes the identification of materials requiring assessment according to the SC Guidance on Nano-RA (detail from Figure 2 of the Guidance on Nano – RA)





**Figure 4:** Step 1: Physicochemical characterisation (detail from Figure 2 of the Guidance on Nano – RA)

**Detailed characterisation data must be provided for each nanomaterial in its pristine form (identity and relevant physicochemical properties)**

## **Chapter 5;** **Appendix B**

Overview of standard methods available at the time of issuing this Guidance.

# Chapter 5: Physicochemical characterisation of nanomaterial (2)

**Table 1A:** Information to be provided on the overall material

Parameters
<b>Name</b>
<b>Description</b>
<b>Intended use</b>
<b>Material composition and purity</b>
<b>Elemental composition</b> Empirical formula of the complete material or relative amounts of elements
<b>Constituent particle size</b> Mean and median minimum external dimension with its number-based distribution
<b>Particle shape</b> Description of the shape, porosity, aspect ratio, EM image of the nanomaterial
<b>Structure</b> Description of the structure, including (relative) thickness of structural elements
<b>Surface chemical composition</b> Description of the composition of the groups or coatings on the particle surface
<b>Production process</b>
<b>Surface area</b>
<b>Appearance</b>
<b>Melting point</b>
<b>Boiling point</b>
<b>Density</b>
<b>Porosity</b>
<b>Dustiness</b>
<b>Formulation</b> Formulation medium Dispersing agents (stabilisers) Auxiliaries Concentration of nanomaterial in dispersion


**Table 1B:** Information on the chemical components

Parameters (incl. specification ranges)
<b>Component 1</b>
<b>Chemical Name</b>
<b>Trade name, common name, other names, synonyms</b>
<b>Registry numbers</b>
<b>Formula</b>
<b>Molecular mass or atomic mass</b>
<b>Elemental composition</b> Empirical formula of this component
<b>Crystal form</b> Form and phase
<b>Purity of the component</b>
<b>Production process component</b>
<b>Component 2</b>
<b>In case of multicomponent particles: Component 2, 3, etc.</b>

**Table 1C:** Extrinsic (media dependent) properties of the material as in the final product

Parameters (incl. specification ranges)
<b>Stability</b>
<b>pH</b>
<b>Solubility</b> (see glossary)
<b>Dissolution/degradation rate</b>
<b>Dispersibility</b>
<b>Surface charge</b>
<b>Agglomeration and/or aggregation state and size</b> Mean and median diameter graphical diagrams of size distribution
<b>Reactivity when applicable</b>

# Chapter 6: Oral exposure assessment of nanomaterial



- If the NM is added to the food (direct exposure for humans/animals):
  - (a) NM (or degradation products) dissolution/degradation in **food/feed matrix**
  - (b) NM (or degradation products) dissolution/degradation in the **gastrointestinal tract**
- If it cannot be determined whether a NM is present in the food/feed matrix it should be assumed that nanomaterial is present.
- Specific considerations for:
  - FCM (transfer by migration or physical release)
  - Feed additives
  - Pesticides

## Chapter 6; Appendix C

Uncertainty analysis of high dissolution/degradation rate

**Figure 5:** Steps in oral exposure assessment (details from Figure 2 of the Guidance on Nano – RA)

# Chapter 7: Hazard identification and hazard characterisation of nanomaterial

## STEP 2: *IN VITRO* DIGESTION (Chapter 7)

Does the material quickly and fully dissolve/degrade under digestive tract conditions?

NO

**STEP 2A – REVIEW EXISTING INFORMATION(a)**  
Review all information on physicochemical and toxicological aspects and/or relevant to grouping/read-across

**STEP 2B - GENERATE NEW *IN VITRO* DATA**  
Including dissolution under lysosomal conditions, genotoxicity, cell toxicity

Is the material persistent OR is there indication of toxicity?

NO

(b)

Argument for waiving the submission of nano-adapted *in vivo* studies

YES

## STEP 3: *IN VIVO* TESTING (Chapter 7)

### STEP 3A - PILOT *IN VIVO* STUDY

A pilot study for dose finding and assessment of ADME (≈ 14d) is recommended

### STEP 3B - *IN VIVO* STUDIES

*In vivo* genotoxicity if required(c) + modified 90-day oral toxicity study + satellite group for assessment of ADME (≈ 14d, 90d, elimination phase); histopathological investigations of gastro-intestinal sites and organs with emphasis on liver, brain, testis and spleen

Do results warrant further testing? (e.g. slow elimination or accumulation and distribution to specific tissues)(d)

YES

## STEP 4: TARGETED IN-DEPTH TESTS (Section 7.8)

For example, additional toxicokinetic studies (e.g. human studies), reproductive and developmental toxicity, immunotoxicity, neurotoxicity, mutagenicity, carcinogenicity, endocrine effects, effects on gut microbiome

- 7.1 Stepwise framework for *in vitro* and *in vivo* testing: overview
- 7.2 *In vitro* degradation tests
- 7.3 Adaptation of Test Guidelines and test designs for toxicity testing of nanomaterial
- 7.4 *In vitro* and *in vivo* genotoxicity testing
- 7.5 *In vitro* toxicity testing
- 7.6 *In vitro* and *in vivo* toxicokinetics testing (ADME)
- 7.7 *In vivo* local and systemic toxicity testing: Adapted repeated-dose 90-day oral toxicity study
- 7.8 Higher tier local and systemic toxicity testing
- 7.9 Read-across
- 7.10 Integrated approaches to testing and assessment

**Figure 6:** Steps in testing (detail from Figure 2 of the Guidance on Nano – RA)

# Step-wise approach

## STEP 2: *IN VITRO* DIGESTION (Chapter 7)

Does the material quickly and fully dissolve/degrade under digestive tract conditions?

NO

### STEP 2A – REVIEW EXISTING INFORMATION(a)

Review all information on physicochemical and toxicological aspects and/or relevant to grouping/read-across

### STEP 2B - GENERATE NEW *IN VITRO* DATA

Including dissolution under lysosomal conditions, genotoxicity, cell toxicity

Is the material persistent OR is there indication of toxicity?

NO  
(b)

Argument for waiving the submission of nano-adapted *in vivo* studies

YES

## STEP 3: *IN VIVO* TESTING (Chapter 7)

### STEP 3A - PILOT *IN VIVO* STUDY

A pilot study for dose finding and assessment of ADME (≈ 14d) is recommended

### STEP 3B - *IN VIVO* STUDIES

*In vivo* genotoxicity if required(c) + modified 90-day oral toxicity study + satellite group for assessment of ADME (≈ 14d, 90d, elimination phase); histopathological investigations of gastro-intestinal sites and organs with emphasis on liver, brain, testis and spleen

Do results warrant further testing? (e.g. slow elimination or accumulation and distribution to specific tissues)(d)

YES

## STEP 4: TARGETED IN-DEPTH TESTS (Section 7.8)

For example, additional toxicokinetic studies (e.g. human studies), reproductive and developmental toxicity, immunotoxicity, neurotoxicity, mutagenicity, carcinogenicity, endocrine effects, effects on gut microbiome

**Step 2:** degradation rate of the NM to a non-NM under representative conditions of the GIT using *in vitro* digestion models (fasted or fed, worst-case conditions)

- Yes? Quickly and fully dissolving NMs may be subjected to standard assessment.
- No? See below.

**Step 2A:** collection of available information and definition of a set of *in vitro* studies to identify hazards and the need of further testing.

# Step-wise approach

## STEP 2: *IN VITRO* DIGESTION (Chapter 7)

Does the material quickly and fully dissolve/degrade under digestive tract conditions?

NO

### STEP 2A – REVIEW EXISTING INFORMATION(a)

Review all information on physicochemical and toxicological aspects and/or relevant to grouping/read-across

### STEP 2B - GENERATE NEW *IN VITRO* DATA

Including dissolution under lysosomal conditions, genotoxicity, cell toxicity

Is the material persistent  
OR is there indication of  
toxicity?

NO

(b)

Argument for waiving  
the submission of nano-  
adapted *in vivo* studies

YES

## STEP 3: *IN VIVO* TESTING (Chapter 7)

### STEP 3A - PILOT *IN VIVO* STUDY

A pilot study for dose finding and assessment of ADME (≈ 14d) is recommended

### STEP 3B - *IN VIVO* STUDIES

*In vivo* genotoxicity if required(c) + modified 90-day oral toxicity study + satellite group for assessment of ADME (≈ 14d, 90d, elimination phase); histopathological investigations of gastro-intestinal sites and organs with emphasis on liver, brain, testis and spleen

Do results warrant further testing? (e.g. slow elimination or accumulation and distribution to specific tissues)(d)

YES

## STEP 4: TARGETED IN-DEPTH TESTS (Section 7.8)

For example, additional toxicokinetic studies (e.g. human studies), reproductive and developmental toxicity, immunotoxicity, neurotoxicity, mutagenicity, carcinogenicity, endocrine effects, effects on gut microbiome

## Step 2B: new *in vitro* data.

- Genotoxic testing:
  - follows the general indications of the EFSA genotoxicity testing strategy (EFSA SC, 2011) considering that Ames test is not suitable for the assessment of nanomaterials and nanoparticles and a mammalian cell gene mutation test (OECD TG 476 or 490) should be preferred
  - should always include an assessment of cellular uptake and a suitable battery of *in vitro* tests (critical endpoints: gene mutation, structural and numerical chromosome aberrations).
  - follow-up with *in vivo* study in case at least one of the *in vitro* tests indicates genotoxicity activity.
- Dissolution under lysosomal conditions
- Cellular toxicity



## STEP 2: *IN VITRO* DIGESTION (Chapter 7)

Does the material quickly and fully dissolve/degrade under digestive tract conditions?

NO

### STEP 2A – REVIEW EXISTING INFORMATION<sup>(a)</sup>

Review all information on physicochemical and toxicological aspects and/or relevant to grouping/read-across

### STEP 2B - GENERATE NEW *IN VITRO* DATA

Including dissolution under lysosomal conditions, genotoxicity, cell toxicity

Is the material persistent OR is there indication of toxicity?

NO

(b)

Argument for waiving the submission of nano-adapted *in vivo* studies

YES

## STEP 3: *IN VIVO* TESTING (Chapter 7)

### STEP 3A - PILOT *IN VIVO* STUDY

A pilot study for dose finding and assessment of ADME (≈ 14d) is recommended

### STEP 3B - *IN VIVO* STUDIES

*In vivo* genotoxicity if required(c) + modified 90-day oral toxicity study + satellite group for assessment of ADME (≈ 14d, 90d, elimination phase); histopathological investigations of gastro-intestinal sites and organs with emphasis on liver, brain, testis and spleen

Do results warrant further testing? (e.g. slow elimination or accumulation and distribution to specific tissues)(d)

YES

## STEP 4: TARGETED IN-DEPTH TESTS (Section 7.8)

For example, additional toxicokinetic studies (e.g. human studies), reproductive and developmental toxicity, immunotoxicity, neurotoxicity, mutagenicity, carcinogenicity, endocrine effects, effects on gut microbiome


- **Step 3**: nano-adapted *in vivo* testing.
- **Step 3A**: pilot *in vivo* study (14-day) for dose-finding and assessment of absorption, tissue distribution, accumulation and excretion (ADME).
- **Step 3B**: toxicity test (90-day) covering local effects in the GIT and organs investigated by histopathology (liver, spleen, brain and gonads). Potential identification of NM with immunological, proliferative, neurotoxic, reproductive organ effects or endocrine-mediated effects.
- **Step 4**: further targeted in depth investigation.

- OECD Test Guidelines (TGs) and other testing protocols require specific **adaptations** for testing NMs (i.e. potential for aggregation/disaggregation, agglomeration/deagglomeration and stability in different media).
- **Ames test** (bacterial reverse mutation) is not considered suitable for NMs, a mammalian cell gene mutation test (OECD TG 476 or 490) should be used instead
- A justification on the selected doses/concentrations should be provided. Studies conducted at **high doses** (*in vitro* >100 µg/mL; *in vivo* >50 for liquid form or >100 mg/kg bw when incorporated in the food matrix) without further information on dispersion and stability or confirmation of cellular/tissue exposure **are insufficient for hazard assessment of NMs.**
- When possible, an **experimental group** exposed to the corresponding non-NM should be included in both *in vitro* and *in vivo* studies (e.g. gavage).
- The **confirmation of exposure** in target tissues (*in vivo*) or in target cells (*in vitro*) **should be demonstrated** and if possible quantified with appropriate techniques;
- The reporting should be **supplemented with the detailed description of the nanospecific issues.**

## Appendices:

- Appendix A. Demonstration fact sheet for component 2
- Appendix B. Characterisation techniques
- Appendix C. Uncertainty analysis of high dissolution/degradation rate
- Appendix D. Additional information on specific regulated products
  - D.1 Feed additives
  - D.2 Pesticides
  - **D.3 Substances used in Food Contact Materials (FCM)**
  - D.4 Nanofibres
  - D.5 Nanocarriers
  - D.6 Fertilisers

**Figure D.1:** Schematic outline and overview of workflow for the nanospecific risk assessment of FCM





OECD TGs require **nano-adaptation** when testing nanomaterials, nanostructured materials and materials containing a fraction of particles at the nanoscale

**Nano-specific risk assessment** should **integrate** the **sectorial** 'conventional' **risk assessment**: the Guidance on Nano - Risk Assessment is **complementary** to the EFSA Guidance Documents on conventional materials

When a conventional material contains a fraction of nanoparticles the risk assessment should consider the risk of **both fractions**: the combined information should cover the safety assessment of the full material



## Subscribe to

[efsa.europa.eu/en/news/newsletters](https://efsa.europa.eu/en/news/newsletters)  
[efsa.europa.eu/en/rss](https://efsa.europa.eu/en/rss)



## Receive job alerts

[careers.efsa.europa.eu](https://careers.efsa.europa.eu) – job alerts



## Follow us on Twitter

[@efsa\\_eu](https://twitter.com/efsa_eu)  
[@plants\\_efsa](https://twitter.com/plants_efsa)  
[@methods\\_efsa](https://twitter.com/methods_efsa)  
[@animals\\_efsa](https://twitter.com/animals_efsa)



## Follow us Linked in

[Linkedin.com/company/efsa](https://www.linkedin.com/company/efsa)



## Contact us

[efsa.europa.eu/en/contact/askefsa](https://efsa.europa.eu/en/contact/askefsa)